Sumati V. Gupta
( out of 115 reviews )

Sumati V. Gupta, MD

Languages spoken: Marathi, English, Hindi

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Hospital South

Clinic 2B, Urology
1950 Circle of Hope
Salt Lake City , UT 84112
801-585-0250
Get Directions

Veterans Administration Medical Center

500 S Foothill Blvd
Salt Lake City , UT 84148
Get Directions

Sumati Gupta, MD, is a tenured Associate Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute (HCI).

Dr. Gupta specializes in the treatment of Genitourinary Cancers (bladder, kidney, prostate and testicular cancer) and the treatment of older adults with cancer (Geriatric Oncology).

Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. Dr. Gupta completed fellowship in Medical Oncology at the University of Utah.

Dr. Gupta serves as the medical director of the Geriatric Oncology clinic (GOAL clinic) and is co- Principal Investigator of the Total Cancer Care project at HCI. Dr. Gupta is a member of the Genitourinary Cancers program and Experimental Therapeutics at HCI and co-chairs the Genitourinary Cancers Research Interest Group in the ORIEN consortium. Dr. Gupta serves on the Data Safety and Monitoring Committee at HCI. As a clinical investigator and physician scientist, Dr. Gupta conducts clinical trials at Huntsman Cancer Institute and investigates mechanisms of treatment resistance to translate to more effective treatment of cancer.

Dr. Gupta also practices at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents and fellows, performs research in Genitourinary Cancers and chairs the VISN-19 Interdisciplinary Cancer Committee.

Specialties

Board Certification

American Board of Internal Medicine (Sub: Medical Oncology)

Patient Rating

4.9 /5
( out of 115 reviews )

The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

The scale on which responses are measured is 1 to 5 with 5 being the best score.

Patient Comments

Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

HUNTSMAN CANCER CENTER

Dr Gupta is very nice and she cares about may health

HUNTSMAN CANCER CENTER

Dr. Gupta is a uniquely committed person. She truly cares about her patients.

HUNTSMAN CANCER CENTER

Thorough

HUNTSMAN CANCER CENTER

Excellent about explaining my treatment

HUNTSMAN CANCER CENTER

she is very nice

HUNTSMAN CANCER CENTER

she is one of the many WONDERFUL doctors at this location

HUNTSMAN CANCER CENTER

I trust Dr. Gupta totally to take care of my medical needs.

HUNTSMAN CANCER CENTER

She explained very well

HUNTSMAN CANCER CENTER

She is very thorough and yet very empathy towards my feelings and making sure I understand where we are going with my treatment

Sumati Gupta, MD, is a tenured Associate Professor in the Division of Oncology, Department of Medicine, at University of Utah‘s Huntsman Cancer Institute (HCI).

Dr. Gupta specializes in the treatment of Genitourinary Cancers (bladder, kidney, prostate and testicular cancer) and the treatment of older adults with cancer (Geriatric Oncology).

Dr. Gupta earned her medical degree from University of Mumbai (KEM) in India. She then completed a residency in Internal Medicine at SUNY Stony Brook, East Meadow program at Nassau University Medical Center. Dr. Gupta then completed a fellowship in Geriatrics at Baylor College of Medicine in Houston, Texas. Dr. Gupta completed fellowship in Medical Oncology at the University of Utah.

Dr. Gupta serves as the medical director of the Geriatric Oncology clinic (GOAL clinic) and is co- Principal Investigator of the Total Cancer Care project at HCI. Dr. Gupta is a member of the Genitourinary Cancers program and Experimental Therapeutics at HCI and co-chairs the Genitourinary Cancers Research Interest Group in the ORIEN consortium. Dr. Gupta serves on the Data Safety and Monitoring Committee at HCI. As a clinical investigator and physician scientist, Dr. Gupta conducts clinical trials at Huntsman Cancer Institute and investigates mechanisms of treatment resistance to translate to more effective treatment of cancer.

Dr. Gupta also practices at the Salt Lake City Veteran Administration hospital where she treats veterans, teaches residents and fellows, performs research in Genitourinary Cancers and chairs the VISN-19 Interdisciplinary Cancer Committee.

Board Certification and Academic Information

Academic Departments Internal Medicine -Associate Professor
Academic Divisions Oncology
Board Certification
American Board of Internal Medicine (Sub: Medical Oncology)

Education history

Undergraduate High School - Atomic Energy Junior College Higher Secondary Certificate
Professional Medical Medical School - King Edward Memorial hospital and Seth G.S Medical College, Mumbai, India MD
Residency Internal Medicine - Nassau University Medical Center Resident
Fellowship Geriatric Medicine - Baylor College of Medicine Fellow
Fellowship Medical Oncology - University of Utah, Huntsman Cancer Institute Fellow

Selected Publications

Journal Article

  1. Hanson HA, Leiser CL, O'Neil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp N (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer epidemiology, biomarkers & prevention, 29(5), 918-926.
  2. Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer chemotherapy and pharmacology, 77(2), 299-308.
  3. Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 78(5), 1059-1071.
  4. Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 124(10), 2115-2124.
  5. Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg J (2019). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 125(4), 533-540.
  6. Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg J (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer, 126(11), 2597-2606.
  7. Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma (2016). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Investigational new drugs, 34(2), 243-52.
  8. Martin C, Leiser CL, O'Neil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson H (2018). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. Journal of the National Cancer Institute, 110(5), 527-533.
  9. Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, GS, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal S (2020). Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. Journal of clinical oncology, 38(16), 1797-1806.
  10. Neeraj Agarwal, Roberto Nussenzveig, Andrew W Hahn, John M Hoffman, Kathryn Morton, Sumati Gupta, Julia Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth Boucher, Benjamin Haaland, Benjamin L Maugha (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer PMID: 31937614 DOI:10.1158/1078-0402 CCR-19 -2591 . Clinical cancer research, 26(9), 2104-2110.
  11. Russell W Madison, Sumati V Gupta, Yasir Y Elamin, Douglas I Lin, Sumanta K Pal, Andrea Necchi, Vincent A Miller, Jeffrey S Ross, Jon H Chung, Brian M Alexander, Alexa B Schrock, John V Heymach, Prasanth Reddy, Siraj Al (2020). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions PMID: 31985116 DOI: 10.1111/bju.15006. BJU international, 125(5), 739-746.
  12. Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury (2021). Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC cancer, 21(1), 593.
  13. Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini B (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.LID - S1470-2045(18)30107-4 [pii]LID - 10.1016/S1470-2045(18)30107-4 [doi]. The Lancet. Oncology, 19, 451-460.
  14. Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, O'Shea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma (2019). Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma.Epub 2018 Oct 9PMID: 30301863 DOI: 10.1158/1535-7163.MCT-17-0957. Molecular cancer therapeutics, 18(1), 185-195.
  15. Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma (2016). Reversible Lysine-Specific Demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-myc in castration-resistant and docetaxel-resistant prostate cancer cells. Prostate cancer and prostatic diseases,
  16. Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Familial cancer, 16(4), 545-550.
  17. Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, O'Connor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar (2021). NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. Journal of the National Comprehensive Cancer Network, 19(9), 1006-1019.
  18. Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clinical genitourinary cancer, 15(4), e599-e602.
  19. Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis S (2018). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clinical genitourinary cancer, 16(2), e373-e382.
  20. Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
  21. Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620.
  22. Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924.
  23. Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin D (2018). Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer discovery, 8(7), 812-821.
  24. Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker H (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. Journal for immunotherapy of cancer, 8(2),
  25. Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde G (2020). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology, 3(5), 695-699.
  26. Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde G (2021). Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU international, 128(5), 607-614.
  27. Lyou Y, Rosenberg JE, Hoffman-Censits J, Quinn DI, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Xu C, Andresen C, Moran S, Daneshmand S, Bajorin D, Pal SK, Grivas (2021). Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical genitourinary cancer,
  28. Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis G (2021). Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. Journal for immunotherapy of cancer, 9(11),
  29. Bleicher J, McGuire LE, Robbins RB, Johnson JE, Fischbuch S, Gupta S, Beck AC, Cohan J (2021). Preoperative Advance Care Planning for Older Adults Undergoing Major Abdominal Surgery. The American journal of hospice & palliative care, 10499091211020276.
  30. Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal S (2020). Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. European urology, 78(6), 916-924.
  31. Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer B (2020). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urologic oncology, 38(1), 1.e1-1.e10.
  32. Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583.
  33. Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urologic oncology, 40(11), 493.e1-493.e7.
  34. Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, O'Day SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta (2023). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer, 11(1),
  35. Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri T (2022). Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. The oncologist,
  36. Sahu KK, Johnson ED, Butler K, Li H, Boucher KM, Gupta (2022). Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. Geriatrics (Basel, Switzerland), 7(6),
  37. Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson J (2023). First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R¿, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. Journal for immunotherapy of cancer, 11(10),
  38. Li H, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Nordblad B, Chigarira B, Gupta S, Maughan BL, Agarwal N, Swami (2023). Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. Cancers, 15(21),
  39. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan B (2023). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. The oncologist, 28(8), 737-e693.
  40. Doroshow DB, O'Donnell PH, Hoffman-Censits JH, Gupta SV, Vaishampayan U, Heath EI, Garcia P, Zhao Q, Yu M, Milowsky MI, Galsky M (2023). Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO precision oncology, 7, e2300095.
  41. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes, 16(1), 16.
  42. Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot (2024). Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. Journal of clinical oncology, JCO2202835.
  43. Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa S (2024). TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals of oncology,
  44. Necchi A, Pouessel D, Leibowitz R, Gupta S, Fléchon A, García-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot (2024). Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Annals of oncology, 35(2), 200-210.
  45. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan B (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). The oncologist, 29(5), 450-e725.
  46. Tripathi N, Gebrael G, Chigarira B, Sahu KK, Balasubramanian I, Caparas C, Mathew Thomas V, Cohan JN, Pelletier K, Maughan BL, Agarwal N, Swami U, Gupta (2024). Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. Cancers, 16(11),
  47. Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta (2024). Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO precision oncology, 8, e2300697.
  48. Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami (2024). Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA network open, 7(5), e249417.
  49. Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC cancer, 24(1), 493.
  50. Grivas P, Kiedrowski LA, Sonpavde GP, Gupta SV, Thomas RA, Gourdin TS, Hardin AI, Hamann KM, Faltas BM, Vogelzang N (2021). Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. Bladder cancer (Amsterdam, Netherlands), 7(2), 143-148.
  51. Swami U, Hong A, Diessner B, Young C, Bunner SH, Xie B, Ramaswamy K, Chastek B, Chaar NE, Gupta (2024). Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future oncology (London, England), 20(32), 1-14.
  52. Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigator (2021). Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. The New England journal of medicine, 385(22), 2036-2046.
  53. Jain RK, Swami U, Bilen MA, Gebrael G, Boucher KM, Braun E, Brown JT, Chahoud J, Gupta S, Agarwal N, Sonpavde G, Maughan B (2025). Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. European urology oncology, 8(4), 952-960.
  54. Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13.
  55. Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3),
  56. Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International journal of radiation oncology, biology, physics,
  57. Masur J, Ratan A, Wierbilowicz K, Ayanambakkam A, Churchman ML, Graham LS, Grass GD, Gupta S, Kern SQ, King J, Myint Z, Rounbehler RJ, Salhia B, Singer EA, Zakharia Y, Paschal BM, Viscuse P (2025). Clinical and Genomic Features of Androgen Indifferent Prostate Cancer. International journal of molecular sciences, 26(2),
  58. Sayegh N, Jo Y, Gebrael G, Tripathi N, Chigarira B, Srivastava A, Nordblad B, Dal E, Hage Chehade C, Mahlow J, Maughan BL, Gupta S, Agarwal N, Swami (2025). Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma. Clinical genitourinary cancer, 23(1), 102287.
  59. Swami U, Hong A, Diessner B, Young C, Bunner SH, Xie B, Ramaswamy K, Chastek B, El Chaar N, Gupta (2024). Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future oncology (London, England), 20(32), 2467-2480.
  60. Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami (2024). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA network open, 7(7), e2423186.

Review

  1. Johnson ED, Butler K, Gupta (2021). Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm. Federal practitioner, 38(Suppl 3), S20-S26.
  2. Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami (2024). Predictors of response to neoadjuvant therapy in urothelial cancer. Critical reviews in oncology/hematology, 194, 104236.
  3. Mahlow J, Gupta (2024). Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance. Urologic oncology,

Editorial

  1. Butterfield A, Gupta (2017). Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor. Translational andrology and urology, 6(6), 1198-1202.

Letter

  1. Galarza Fortuna GM, Swami U, Gupta (2025). Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)". Journal for immunotherapy of cancer, 13(5),

Abstract

  1. Gupta (2002). Retrospective study on the effect of chronic ACE inhibitor therapy on inter-dialysis weight gain in patients on hemodialysis. Renal failure, Jul;24(4), 461-6.
  2. Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz AA, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urotheial carcinoma of the bladderÏ.
  3. Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde (2017). Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.
  4. Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal (2017). Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC).
  5. Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan B (2017). Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer.
  6. Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn, AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
  7. Pandha HS, Ralph C, Harrington K, Curti BD, Sanborn RE, Akerley WL, Gupta S, Rudin CM, Rosenberg JE, Kaufman DR, Schmidt EV, Grose M, Shafren (2017). Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.
  8. Gong J, Chung VM, Picus J, Tagawa ST, Gupta S, Poore J, Peterson C, Benaim E, Pal S (2017). Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study.
  9. Choueiri TK, Larkin JMG, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, Powles T, McDermott DF, Robbins PB, Chism DD, Cho DC, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, di Pietro A, Rini B (2017). First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
  10. Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde (2017). Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.
  11. Agarwal N, Heemers H, Farnham JM, Patel SB, Gill D, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright L (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC).
  12. Gupta (2016). A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes.
  13. Gupta S, Weston A, Bearrs J, Soldi R, Sharma (2015). Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells.
  14. Gupta S, Albertson DJ, Parnell T, Dalley B, O Shea J, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal (2017). Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).
  15. Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Milis SZ, Ali S (2017). Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients.
  16. Hahn AW, Gill DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan B (2017). Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC).
  17. Ahmad Halwani, Zachary Burningham, Kelli M Rasmussen, Vikas Patil, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Saue (2017). Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evidence From the Veterans Health Administration.
  18. A Necchi,D Pouessel, R Leibowitz-Amit, A Flechon, S Gupta, P Barthelemy, M Maio, X Zhu, E Asatiani, G Serbest, H Zhen, Y Lorio (2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA).
  19. Gupta, (2018). ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma.
  20. Stenehjem D, Gupta S, Wade M, Gilcrease G, Garrido-Laguna I, Weis JR, Whisenant J, Sharma (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. 2016,
  21. Petros Grivas, Gregory Russell Pond, Rebecca J Nagy, Pedro C. Barata, Prateek Mendiratta, Dharmesh Gopalakrishnan, Alexandra Drakaki, Sumati Gupta, Neeraj Agarwal, Jue Wang, Bishoy Faltas, Ulka N. Vaishampayan, Gurudatta Naik, Bradley Alexander McGregor, Sumanta K. Pal, Lesli Ann Kiedrowski, Richard B. Lanman, Guru Sonpavd (2018). Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). ASCO Annual Meeting 2018.
  22. Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer, Ahmad Halwan (2017). The role of academic affiliation in the treatment of metastatic castrate-resistant prostate cancer in the Veterans Health Administration Abstract- AVAHO 2017.
  23. Ahmad Halwani, Kelli M. Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie N. Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C, Saie (2017). Racial Disparities in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Evidence from the Veteran's Health Administration (VHA) AACR.
  24. Sumanta Pal, Vincent Chun, Scott Tagawa, Joel Picus, Sumati Gupta, Julie Poore, Christine Peterson and Ely Benai (2017). RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Metastatic Bladder Cancer.
  25. Jacob Adashek, Sumanta K. Pal, Vincent M. Chung, Scott T. Tagawa, Joel Picus, Hani M. Babiker, Sumati Gupta, Raymond Couric Wadlow, Julie Poore, Christine Peterson, Ely Benai (2018). Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC). ASCO Annual Meeting 2018.
  26. Sumati Gupta, Andrew Butterfield, Timothy Parnell, Alexis Weston, Mohan Kaadige, Sunil Sharm (2018). Reversible LSD1 (KDM1A) inhibition with HCI2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners.
  27. Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, David I. Quinn, Daniel Peter Petrylak, Matt D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris III, Jessica Rearden, Corina Andresen, Hao Wang, Siamak Daneshmand, Dean F. Bajorin, and Sumanta K. Pa (2020). Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings. . 38(15_suppl), 5038-5038.
  28. Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K. Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, and Guru Sonpavd (2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. . 38(15_suppl), 5043-5043.
  29. Lesli Ann Kiedrowski, Roby Antony Thomas, Nicholas J. Vogelzang, Guru Sonpavde, Sumati Gupta, Theodore Stewart Gourdin, Bishoy Morris Faltas, Rebecca Nagy, Richard B. Lanman, and Petros Griva (2020). FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC). . 38(6_suppl), 565-565.
  30. Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, David I. Quinn, Daniel Peter Petrylak, Matt D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, Jessica Rearden, Yining Ye, Hao Wang, Susan Moran, Siamak Daneshmand, Dean F. Bajorin, and Sumanta K. Pa (2020). Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC). . 38(6_suppl), 576-576.
  31. Shilpa Gupta, Guru Sonpavde, Christopher J. Weight, Bradley Alexander McGregor, Sumati Gupta, Benjamin Louis Maughan, Xiao X. Wei, Ewan Gibb, Bharat Thyagarajan, David Johnson Einstein, Christopher B. Dechet, William Thomas Lowrance, Paari J Murugan, Kerry L. Kilbridge, Neeraj Agarwal, Elai Davicioni, Markus Eckstein, Matthew Mossanen, Mark A. Preston, and Badrinath R. Konet (2020). Pl Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. 38(6_suppl), 439-439.
  32. Petros Grivas, Yohann Loriot, Susan Feyerabend, Rafael Morales-Barrera, Min Yuen Teo, Nicholas J. Vogelzang, Enrique Grande, Yousef Zakharia, Nabil Adra, Ajjai Shivaram Alva, Andrea Necchi, Sumati Gupta, Debra Hannah Josephs, Alejo Rodriguez-Vida, Sandy Srinivas, Kenton Wride, Daleen Thomas, Rachel Dusek, Dale L. Nepert, and Simon Chowdhur (2020). Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial. . 38(6_suppl), 440-440.
  33. Sumati Gupta, Benjamin Louis Maughan, Christopher B. Dechet, William Thomas Lowrance, Brock O Neil, Kristine E. Kokeny, Shane Lloyd, Jonathan David Tward, Kenneth M. Boucher, and Neeraj Agarwa (2020). NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. 38(6_suppl), TPS605-TPS605.
  34. Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M. Boucher, Benjamin Haaland, and Neeraj Agarwa (2020). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. 38(6_suppl), 125-125.
  35. Benjamin Louis Maughan, Alejandro Sanchez, Brock B. O'Neil, William Thomas Lowrance,Christopher B. Dechet, Danel Joseph Albertson, Deepika Sirohi, Sumati Gupta, Umang Swami, and Neeraj Agarwa (2020). A phase 1b/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AteoVax). 38(6_suppl), TPS382-TPS382.
  36. Benjamin Louis Maughan, Roberto Nussenzveig, Umang Swami, Sumati Gupta, and Neeraj Agarwa (2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response. 38(6_suppl), TPS267-TPS267.
  37. Sergiusz Wesolowski Roberto Nussenzveig, Victor Sacristan Santos, John Esther, Divyam Goel, Umang Swami, Sumati Gupta, Benjamin Louis Maughan, Mark Yandell, Petros Grivas, and Neeraj Agarwa (2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI). 38(6_suppl), 570-570.
  38. Wendy Kohlmann, David Nix, Aaron Atkinson, Kenneth M Boucher, Jill Kolesar, Eric A. Singer, Stephen B. Edge, Branda Quintana, Michelle L. Churchman, Bingjian Feng, Laura Graham, John D. Carpten, Alejandro Sanchez, Yousef Zakharia, Lindsey Byrne, Rohit K. Jain, Kenneth G. Nepple, Ahmad Shabsigh, Jad Chahoud, and Sumati Gupt (2022). Inherited germline variants in urothelial cancer: A multicenter whole-exome sequencing analysis.
  39. S. Gupta , A. Hong , N.N. El-Chaar , C. Young , K. Ramaswamy , B. Xie , S. Bunner , B. Diessner , U. Swam (2022). Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
  40. Sumati Gupta, Benjamin Maughan, Manish Kohli, Bradley Cairns, Umang Swami, Neeraj Agarwa (2022). A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE) .
  41. Manish Kohli; Jodie Wong; Yijun Tian; Amir Bitaraf; Claire Hanson; Matt Larsen; Jennifer Lloyd; Julia Batten; Neeraj Agarwal; Umang Swami; Benjamin Maughan; Sumati Gupta; Jonathan Twar (2023). Abstract 6023: Plasma methylome landscape across the spectrum of prostate cancer progression, and differentially methylated region (DMR) based biomarkers of hormonal therapy failure in metastatic hormone-sensitive prostate cancer. 83(7_Supplement), 6023.
  42. Umang Swami, Caitlin Faust, Samuel Leonhart, Benjamin Haaland, Kristen Jones, Haoran Li, Kamal Kant Kant Sahu, Vinay Mathew Thomas, Tenzin Kunsang Phunrab, Julia Batten, Lindsay Maxwell, Jennifer Lloyd, Manish Kohli, Sumati Gupta, Kelli Thorne, Benjamin L. Maughan, Neeraj Agarwal Huntsman Cancer Institute at the University of Utah, Salt Lake City, U (2023). ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). . 41(6_suppl), TPS294.
  43. Nishita Tripathi; Yeonjung Jo; Nicolas Sayegh; Beverly Chigarira; Blake Nordblad; Vinay Mathew Thomas; Benjamin Haaland; Roberto Nussenzveig; Sumati Gupta; Neeraj Agarwal; Umang Swami; Benjamin L. Maugha (2022). Abstract 5955: Tumor genomic landscape in patients (pts) with and without liver metastasis in metastatic urothelial carcinoma (mUC). . 82(12_Supplement), 5995.
  44. Sheetal Hardikar; Christopher R. Weil; Shane Lloyd; Jessica N. Cohan; Mark A. Supiano; Jennifer Ose; Anita R. Peoples; Sumati V. Gupta; Kaitlyn Pelletier; Martine Extermann; Erin M. Siegel; David Shibata; Cornelia M. Ulric (2022). Abstract 36: Treatment patterns in stage I-III colorectal cancer patients over 65 years of age. 82(12_Supplement), 36.
  45. Kamal Kant Kant Sahu, Nishita Tripathi, Beverly Chigarira, Nicolas Sayegh, Vinay Mathew Thomas, Haoran Li, Yeonjung Jo, Georges Gebrael, Puja Iyer, Roberto Nussenzveig, Neeraj Agarwal, Benjamin L. Maughan, Sumati Gupta, Umang Swami Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT; University of Utah, Salt Lake City, U (2023). Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC). . 41(6_suppl), 561.
  46. Shilpa Gupta, Ewan Gibb, Guru P. Sonpavde, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Bradley Alexander McGregor, Christopher Weight, Xiao X. Wei, David Johnson Einstein, Christopher B. Dechet, Mark A. Preston, Matthew Mossanen, Bharat Thygarajan, Markus Eckstein, C. Marcela Diaz-Montero, Paari J. Murugan, Peter C. Black, Badrinath R. Konet (2022). Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy. . 40(6_suppl), 528.
  47. Jonathan David Tward, Skyler B Johnson, Kristine E. Kokeny, Shane Lloyd, Donald Maurice Cannon, Christopher B. Dechet, Brock ONeil, Robert Stephenson, Kenneth M. Boucher, Sumati Gupta, Umang Swami, Benjamin L. Maughan, Neeraj Agarwal Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; University of Utah, Salt Lake City, UT; Huntsman Cancer Hospital, Salt Lake City, U (2023). Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-na&iuml;ve men with oligometastatic prostate cancer to bone. 41(6_suppl), 156.
  48. Kamal Kant Kant Sahu, Haoran Li, Vinay Mathew Thomas, Mallory Benson, Josiah Hawaks, Julian Brown, Kelli Thorne, Kathy Sherwin, Jackson Cheney, Kenneth M. Boucher, Sumati Gupta, Manish Kohli, Umang Swami, Neeraj Agarwal, Benjamin L. Maughan Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; University of Utah, Salt Lake City, UT; Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT; Salt Lake City, U (2023). A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with &ldquo;BCRAness&rdquo; genotype (ROAR). 41(6_suppl), 364.
  49. Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Flechon, Chethan Ramamurthy, Nancy B. Davis, Alejandro Recio-Boiles, Cora N. Sternberg, Astha Bhatia, Cabilia Pichardo, Mitch Sierecki, Julia Tonelli, Huafeng Zhou, Scott T. Tagawa, Yohann Lorio (2023). Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. . 41(6_suppl), 518.
  50. Samantha Greenberg, Elizabeth Orlando, Morgan Devlin, Sara Low, Amanda Anson, Brock O Neil, Wendy Kohlmann, Bob Wong, Christopher B. Dechet, Alejandro Sanchez, Jonathan David Tward, Skyler B Johnson, Neeraj Agarwal, Manish Kohli, Sumati Gupta, Umang Swami, Benjamin L. Maughan; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Huntsman Cancer Institute, Salt Lake City, UT; University of Utah, Salt Lake City, U (2022). Comparing pretest video genetic education for prostate cancer patients: Do patients need assistance? . 40(16_suppl), 5061.
  51. Neal Shiv Chawla, Nishita Tripathi, Nicolas Sayegh, Ameish Govindarajan, Nazli Dizman, Zeynep Busra Zengin, Luis A Meza, Ramya Muddasani, Alex Chehrazi-Raffle, Sabrina Salgia, Jasnoor Malhotra, Joann Hsu, Errol James Philip, Cristiane Decat Bergerot, Yung Lyou, Umang Swami, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Sumanta K. Pa (2022). Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. 40(6_suppl), 561.

Other

  1. Kharkar VJ, Ast A, Gupta S, Sharma (2016). LSD2/KDM1B/AOF1 and Human Cancer Pathways: A Literature Review. 1(1), 1-5.
  2. Hillary Finch, Clark Low, Sumati Gupt (2018). FGFR pathways and their role in oncologic therapy: Focus on Phase I Newsletter.
  3. Gupta (2015). Epigenetics in Bladder Cancer.
  4. Nikita Pandya, Robert Hanlon, Andrew Butterfield,Sumati Gupt (2017). Epigenetics in Cancer: A Review.